NO20053529L - Lymfotoksin-beta-reseptormedikamenter i kombinasjon med kjemoterapeutiske midler - Google Patents
Lymfotoksin-beta-reseptormedikamenter i kombinasjon med kjemoterapeutiske midlerInfo
- Publication number
- NO20053529L NO20053529L NO20053529A NO20053529A NO20053529L NO 20053529 L NO20053529 L NO 20053529L NO 20053529 A NO20053529 A NO 20053529A NO 20053529 A NO20053529 A NO 20053529A NO 20053529 L NO20053529 L NO 20053529L
- Authority
- NO
- Norway
- Prior art keywords
- combination
- beta receptor
- lymphotoxin
- chemotherapeutic agents
- receptor drugs
- Prior art date
Links
- 102000018170 Lymphotoxin beta Receptor Human genes 0.000 title abstract 3
- 108010091221 Lymphotoxin beta Receptor Proteins 0.000 title abstract 3
- 239000002246 antineoplastic agent Substances 0.000 title abstract 2
- 229940127089 cytotoxic agent Drugs 0.000 title abstract 2
- 229940079593 drug Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000000654 additive Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 238000002648 combination therapy Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000018 receptor agonist Substances 0.000 abstract 1
- 229940044601 receptor agonist Drugs 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
- 230000011664 signaling Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43518502P | 2002-12-20 | 2002-12-20 | |
| PCT/US2003/041243 WO2004058183A2 (en) | 2002-12-20 | 2003-12-22 | Lymphotoxin beta receptor agents in combination with chemotherapeutic agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20053529D0 NO20053529D0 (no) | 2005-07-19 |
| NO20053529L true NO20053529L (no) | 2005-09-20 |
Family
ID=32682180
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20053529A NO20053529L (no) | 2002-12-20 | 2005-07-19 | Lymfotoksin-beta-reseptormedikamenter i kombinasjon med kjemoterapeutiske midler |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20060134102A1 (enExample) |
| EP (1) | EP1585547A4 (enExample) |
| JP (1) | JP2006513225A (enExample) |
| KR (1) | KR20050094819A (enExample) |
| CN (1) | CN1753692A (enExample) |
| AU (1) | AU2003303339A1 (enExample) |
| BR (1) | BR0317573A (enExample) |
| CA (1) | CA2509495A1 (enExample) |
| EA (1) | EA200501019A1 (enExample) |
| IS (1) | IS7900A (enExample) |
| MX (1) | MXPA05006663A (enExample) |
| NO (1) | NO20053529L (enExample) |
| PL (1) | PL377611A1 (enExample) |
| RS (1) | RS20050481A (enExample) |
| WO (1) | WO2004058183A2 (enExample) |
| ZA (1) | ZA200505543B (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6312691B1 (en) * | 1996-01-26 | 2001-11-06 | Jeffrey L. Browning | Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents |
| US5925351A (en) | 1995-07-21 | 1999-07-20 | Biogen, Inc. | Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease |
| TR200602095T2 (tr) * | 2000-10-13 | 2007-02-21 | Biogen Idec Ma Inc. | Hümanize Anti-LT-Beta-R antikorları |
| TW200416044A (en) * | 2002-07-01 | 2004-09-01 | Biogen Inc | Humanized anti-lymphotoxin β receptor antibodies |
| AU2003256299A1 (en) * | 2002-07-01 | 2004-01-19 | Human Genome Sciences, Inc. | Antibodies that specifically bind to reg iv |
| AU2003299984A1 (en) * | 2002-12-20 | 2004-07-22 | Biogen Idec Ma Inc. | Multivalent lymphotoxin beta receptor agonists and therapeutic uses thereof |
| US20050163782A1 (en) * | 2003-06-27 | 2005-07-28 | Biogen Idec Ma Inc. | Modified binding molecules comprising connecting peptides |
| KR20060132006A (ko) * | 2004-03-23 | 2006-12-20 | 비오겐 아이덱 엠에이 아이엔씨. | 수용체 커플링제 및 이의 치료적 용도 |
| WO2006074399A2 (en) * | 2005-01-05 | 2006-07-13 | Biogen Idec Ma Inc. | Multispecific binding molecules comprising connecting peptides |
| DK1866339T3 (da) | 2005-03-25 | 2013-09-02 | Gitr Inc | GTR-bindende molekyler og anvendelser heraf |
| WO2006125632A2 (en) * | 2005-05-24 | 2006-11-30 | Rechtsanwalt Dr. Martin Prager Als Insolvenzverwalter Über Das Vermögen Der Xantos Biomedicine Ag, Pluta Rechtsanwalts Gmbh | Agonistic antibodies that bind to the tweak receptor fn14 and thereby modulate adiposity-associated phenotypes as well as their use in therapy |
| CA2655411A1 (en) * | 2006-06-15 | 2007-12-21 | Biogen Idec Ma Inc. | Combination therapy employing lymphotoxin beta receptor binding molecules in combination with second agents |
| BRPI0715580A2 (pt) | 2006-10-12 | 2014-06-10 | Genentech Inc | ''ANTICORPO ANTI-LINFOTOXINA-a (LTa) ISOLADO, ANTICORPO HUMANIZADO, ANTICORPOS ANTI-LINFOTOXINA-a,COMPOSIÇÃO DE ANTICORPO,ANTICORPO ANTI-IDIOTIPO,HIBRIDOMA,ANTICORPO,ÁCIDO NUCLÉICO ISOLADO, VETOR DE EXPRESSÃO,CÉLULA HOSPEDEIRA,MÉTODO DE PRODUÇÃO DE UM ANTICORPO,MÉTODO PARA INIBIR A PROLIFERAÇÃO CELULAR ATIVADA POR LTa, MÉTODO PARA TRATAR UM DISTURBIO AUTO-IMUNE, ARTIGOS MANUFATURADOS, MÉTODO PARA DIVULGAR UM ANTICORPO E MÉTODO PARA EMBALAR O ANTICORPO'' |
| KR20090071652A (ko) * | 2006-10-20 | 2009-07-01 | 바이오겐 아이덱 엠에이 인코포레이티드 | 가용성 림프독소-베타-수용체를 이용한 탈수초성 장애의 치료 |
| US8338376B2 (en) * | 2006-10-20 | 2012-12-25 | Biogen Idec Ma Inc. | Compositions comprising variant LT-B-R-IG fusion proteins |
| ES2776406T3 (es) | 2007-07-12 | 2020-07-30 | Gitr Inc | Terapias de combinación que emplean moléculas de enlazamiento a GITR |
| MX389194B (es) | 2015-10-06 | 2025-03-20 | Univ Minnesota | Compuestos terapéuticos y métodos. |
| JOP20190100A1 (ar) | 2016-11-19 | 2019-05-01 | Potenza Therapeutics Inc | بروتينات ربط مولد ضد مضاد لـ gitr وطرق استخدامها |
| EP3807401A1 (en) | 2018-06-15 | 2021-04-21 | Universität Bern | LIGANDS TO LIGHT OR ITS RECEPTOR LTßR FOR USE IN HAEMATOLOGIC MALIGNANCIES |
| KR102232659B1 (ko) * | 2018-07-16 | 2021-03-26 | 전북대학교 산학협력단 | 항원전달용 폴리펩타이드, 이를 포함하는 Fc-융합 단백질 및 이의 용도 |
| WO2020081841A1 (en) | 2018-10-19 | 2020-04-23 | Regents Of The University Of Minnesota | Nk engager molecules and methods of use thereof |
| WO2021116337A1 (en) * | 2019-12-11 | 2021-06-17 | Cilag Gmbh International | Multispecific binding molecules comprising ltbr and edb binding domains and uses thereof |
| CN115057938B (zh) * | 2022-06-24 | 2023-01-06 | 广东菲鹏制药股份有限公司 | 抗新型冠状病毒人源化多价结合蛋白及其应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5618920A (en) * | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US6312691B1 (en) * | 1996-01-26 | 2001-11-06 | Jeffrey L. Browning | Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents |
| CA2211443A1 (en) * | 1995-01-26 | 1996-08-01 | Biogen, Inc. | Lymphotoxin-.alpha./.beta. complexes and anti-lymphotoxin-beta receptor antibodies as anti-tumor agents |
| US5925351A (en) * | 1995-07-21 | 1999-07-20 | Biogen, Inc. | Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease |
| CA2269614A1 (en) * | 1996-10-25 | 1998-04-30 | Biogen, Inc. | Soluble lymphotoxin-beta receptors, anti-lymphotoxin receptor antibodies, and anti-lymphotoxin ligand antibodies as therapeutic agents for the treatment of immunological diseases |
| US7060667B1 (en) * | 1998-01-30 | 2006-06-13 | Biogen Idec Ma, Inc. | Treatment of follicular lymphomas using inhibitors of the LT pathway |
| US7442776B2 (en) * | 1999-10-08 | 2008-10-28 | Young David S F | Cancerous disease modifying antibodies |
| TR200602095T2 (tr) * | 2000-10-13 | 2007-02-21 | Biogen Idec Ma Inc. | Hümanize Anti-LT-Beta-R antikorları |
| US7361343B2 (en) * | 2003-01-21 | 2008-04-22 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of CD63 |
| TW200416044A (en) * | 2002-07-01 | 2004-09-01 | Biogen Inc | Humanized anti-lymphotoxin β receptor antibodies |
| AU2003299984A1 (en) * | 2002-12-20 | 2004-07-22 | Biogen Idec Ma Inc. | Multivalent lymphotoxin beta receptor agonists and therapeutic uses thereof |
| US7393531B2 (en) * | 2003-01-21 | 2008-07-01 | Arius Research Inc. | Cytotoxicity mediation of cells evidencing surface expression of MCSP |
| KR20060132006A (ko) * | 2004-03-23 | 2006-12-20 | 비오겐 아이덱 엠에이 아이엔씨. | 수용체 커플링제 및 이의 치료적 용도 |
-
2003
- 2003-12-22 BR BR0317573-1A patent/BR0317573A/pt not_active IP Right Cessation
- 2003-12-22 CN CNA2003801099160A patent/CN1753692A/zh active Pending
- 2003-12-22 KR KR1020057011596A patent/KR20050094819A/ko not_active Ceased
- 2003-12-22 EP EP03808561A patent/EP1585547A4/en not_active Withdrawn
- 2003-12-22 WO PCT/US2003/041243 patent/WO2004058183A2/en not_active Ceased
- 2003-12-22 RS YUP-2005/0481A patent/RS20050481A/sr unknown
- 2003-12-22 AU AU2003303339A patent/AU2003303339A1/en not_active Abandoned
- 2003-12-22 JP JP2004564044A patent/JP2006513225A/ja active Pending
- 2003-12-22 EA EA200501019A patent/EA200501019A1/ru unknown
- 2003-12-22 CA CA002509495A patent/CA2509495A1/en not_active Abandoned
- 2003-12-22 MX MXPA05006663A patent/MXPA05006663A/es not_active Application Discontinuation
- 2003-12-22 PL PL377611A patent/PL377611A1/pl unknown
-
2005
- 2005-06-17 US US11/156,109 patent/US20060134102A1/en not_active Abandoned
- 2005-06-20 IS IS7900A patent/IS7900A/is unknown
- 2005-07-08 ZA ZA200505543A patent/ZA200505543B/xx unknown
- 2005-07-19 NO NO20053529A patent/NO20053529L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| KR20050094819A (ko) | 2005-09-28 |
| WO2004058183A3 (en) | 2004-12-09 |
| ZA200505543B (en) | 2006-12-27 |
| MXPA05006663A (es) | 2005-09-30 |
| WO2004058183A2 (en) | 2004-07-15 |
| CA2509495A1 (en) | 2004-07-15 |
| EA200501019A1 (ru) | 2006-06-30 |
| JP2006513225A (ja) | 2006-04-20 |
| EP1585547A2 (en) | 2005-10-19 |
| US20060134102A1 (en) | 2006-06-22 |
| PL377611A1 (pl) | 2006-02-06 |
| NO20053529D0 (no) | 2005-07-19 |
| IS7900A (is) | 2005-06-20 |
| CN1753692A (zh) | 2006-03-29 |
| AU2003303339A1 (en) | 2004-07-22 |
| RS20050481A (sr) | 2007-08-03 |
| EP1585547A4 (en) | 2006-10-25 |
| BR0317573A (pt) | 2005-11-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20053529L (no) | Lymfotoksin-beta-reseptormedikamenter i kombinasjon med kjemoterapeutiske midler | |
| Han et al. | Direct evidence for the role of neuropeptide Y in sympathetic nerve stimulation-induced vasoconstriction | |
| CY1113159T1 (el) | Ανταγωνιστες υποδοχεα γλυκαγονης, παρασκευη και θεραπευτικες χρησεις | |
| BRPI0413563A (pt) | compostos e composições como inibidores de atividade do receptor de quìnase de tirosina | |
| TW200731968A (en) | Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and/or H3 receptor antagonist/inverse agonist | |
| NO20052496D0 (no) | Selekterte CGRP antagonister, fremgangsmater for fremstilling derav og anvendelse derav som medikamenter. | |
| SG146653A1 (en) | Methods and reagents for the treatment of immunoinflammatory disorders | |
| CY1109543T1 (el) | Βασικοι μη-πεπτιδικοι ανταγωνιστες βραδυκινινης και 5 φαρμακευτικες συνθεσεις απο αυτους | |
| NO20064193L (no) | fremgangsmate for a modulere cytokinaktivitet, beslektede reagenser | |
| WO2007146414A3 (en) | Combination therapy employing lymphotoxin beta receptor binding molecules in combination with second agents | |
| NO2013017I2 (no) | (a)dekstrometorfan eller et farmasøytisk akseptabelt salt derav, for eksempel dekstrometorfanhydrobromid og (b) quinidin eller etfarmasøytisk akseptabelt salt derav, for eksempel quinidinsulfat | |
| NO20010062L (no) | Bifenylsulfonamider som duale angiotensin-endotelin- reseptorantagonister | |
| WO2007075555A3 (en) | Combination of an h3 antagonist/inverse agonist and an appetite suppressant | |
| NO20050827L (no) | Anvendelse av interferon-B ved behandling av nyresvikt | |
| DK1316801T3 (da) | Sammensætninger og fremgangsmåder til detektion og behandling af sygdomme og tilstande, som er relateret til kemokinreceptorer | |
| BRPI0511272A (pt) | métodos e reagentes para o tratamento de distúrbios imunoinflamatórios | |
| Mur et al. | Neuropsychological profile in bipolar disorder: a preliminary study of monotherapy lithium‐treated euthymic bipolar patients evaluated at a 2‐year interval | |
| WO2009055001A3 (en) | Methods of treating aging and methods of screening candidate agents therefor | |
| DK1545537T3 (da) | Alfa-7-nikotinreceptoragonister og statiner i kombination | |
| WO2007095161A3 (en) | Methods and compositions for treating disorders associated with increased bone turnover and osteopenia | |
| DK1509618T3 (da) | Autoimmune sygdomme og NADPH-oxidasedefekter | |
| CY1114307T1 (el) | Συνθεσεις που περιεχουν αικουορινη και μεθοδοι που τις χρησιμοποιουν | |
| Boucai et al. | Selpercatinib-induced hypothyroidism through off-target inhibition of type 2 iodothyronine deiodinase | |
| Cunha‐Reis et al. | VPAC1 and VPAC2 receptor activation on GABA release from hippocampal nerve terminals involve several different signalling pathways | |
| DE602004027048D1 (de) | Verbindungen und methoden für das downregulating der effekte von tgf-beta |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |